Agios Pharmaceuticals, Inc. $AGIO Shares Sold by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP lessened its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 72.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,900 shares of the biopharmaceutical company's stock after selling 152,647 shares during the quarter. Seven Fleet Capital Management LP owned about 0.10% of Agios Pharmaceuticals worth $2,112,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AGIO. T. Rowe Price Investment Management Inc. acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth $25,000. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals in the first quarter valued at $40,000. Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals in the second quarter valued at $43,000. Caitong International Asset Management Co. Ltd acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at $49,000. Finally, Eurizon Capital SGR S.p.A. acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at $72,000.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $33.99 on Thursday. The firm's fifty day moving average is $35.91 and its two-hundred day moving average is $31.56. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00. The firm has a market cap of $2.03 billion, a PE ratio of -4.85 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million for the quarter, compared to analysts' expectations of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. Research analysts predict that Agios Pharmaceuticals, Inc. will post -5.8 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Truist Financial cut their target price on Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. TD Cowen upgraded Agios Pharmaceuticals to a "strong-buy" rating in a research note on Monday. Royal Bank Of Canada lifted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a "sector perform" rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. boosted their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $41.25.

Insider Activity

In other news, insider Sarah Gheuens sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider owned 54,645 shares of the company's stock, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source